|
Composition:
Lamivudine
............................................................150
mg
Zidovudine USP
............................................................300
mg
Nevirapine
............................................................200
mg
Indications:
Dectrovir-N is indicated for the
treatment of HIV infection, once
patients have been stabilized on
the maintenance regimen of
nevirapine 200 mg bd, and have
demonstrated adequate
tolerability to nevirapine.
Description:
Nevirapine is a non-nucleoside reverse transcriptase
inhibitor (nNRTI) with activity
against Human Immunodeficiency
Virus Type 1 (HIV-1). HIV-2 RT
and eukaryotic DNA polymerases
(such as human DNA polymerases
alpha, beta, or sigma) are not
inhibited by nevirapine.
Nevirapine is, in general, only
prescribed after the immune
system has declined and
infections have become evident.
It is always taken with at least
one other HIV medication such as
Retrovir or Videx. The virus can
develop resistance to nevirapine
if the drug is taken alone,
although even if used properly,
nevirapine is effective for only
a limited time.
Nevirapine binds directly to
reverse transcriptase (RT) and
blocks the RNA-dependent and
DNA-dependent DNA polymerase
activities by causing a
disruption of the enzyme's
catalytic site. The activity of
nevirapine does not compete with
template or nucleoside
triphosphates.
Side Effects
In controlled clinical trials,
the most common
Nevirapine
side effect was rash, which in
7.6% of subjects was considered
severe. Increases in the liver
enzymes occurred in 5-10% of
subjects compared with 2-5% in
controls.
CONTRAINDICATIONS:
Nevirapine is contraindicated in patients with clinically
significant hypersensitivity to
any of the components contained
in the tablet or the oral
suspension.
Drug Interaction
Nevirapine is principally metabolized by the liver via the
cytochrome P450 isoenzymes, 3A4
and 2B6. Nevirapine is known to
be an inducer of these enzymes.
As a result, drugs that are
metabolized by these enzyme
systems may have lower than
expected plasma levels when
coadministered with nevirapine.
Dosage:
Adults: 1 tablet twice daily or
as per the physician’s advice.
Presentations:
30
tablets
MRP
Retailer Stockist
675.00
540.00 486.00
|
